Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 18, 2012

Majority in GEN Poll Sees at Least Some Use for Bioeconomy Blueprint

  • A majority of GEN poll takers predicts at least some usefulness from President Barack Obama’s recently released National Bioeconomy Blueprint, detailing measures by which Washington intends to apply biological research innovations toward national challenges that include health, food, energy, and the environment. Exactly one-third (33.3%) of respondents said they thought the Blueprint would be “very” useful, while just over one-quarter (25.9%) said it would be “somewhat” useful. However, roughly another one-third (31.5%) concluded that the Blueprint was “not very” useful. The remaining 9.3% was undecided.

    The Blueprint’s five priorities include supporting “R&D investments that will provide the foundation for the future U.S. bioeconomy,” followed by increasing the focus on translational and regulatory sciences, reforming regulations, updating training programs, and identifying and supporting opportunities for public-private partnerships.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »